quantisnow
FeedTopReportsPricing
⌘K
Live feed
15:15:00·63d
PRRelease
Agenus Inc. logo

Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL

AGEN· Agenus Inc.
Health Care
Original source

Companies

  • AGEN
    Agenus Inc.
    Health Care

Recent analyst ratings

  • Jun 4UpdateH.C. Wainwright$25.00
  • Jul 19UpdateRobert W. Baird$8.00
  • Jul 18UpdateWilliam Blair-
  • Jul 18UpdateH.C. Wainwright$9.00
  • Jun 6UpdateRobert W. Baird$8.00
  • Jun 6UpdateRobert W. Baird$80.00

Related

  • INSIDER2d
    SEC Form 4 filed by Armen Garo H
  • PR2d
    Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
  • PR2d
    Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
  • SEC3d
    SEC Form PRE 14A filed by Agenus Inc.
  • PR6d
    Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
  • INSIDER10d
    SEC Form 4 filed by Harrison Thomas L
  • INSIDER17d
    SEC Form 4 filed by Armen Garo H
  • PR21d
    Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022